109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
巨噬细胞膜包被的纳米载体在心肌梗死中的应用：靶向心脏治疗的范式转变
Authors Wang L, Wang K, Zheng H
Received 13 June 2025
Accepted for publication 1 October 2025
Published 7 November 2025 Volume 2025:20 Pages 13499—13525
DOI https://doi.org/10.2147/IJN.S546817
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Jie Huang
Liping Wang,1 Kaili Wang,2 Hongjian Zheng2
1Department of Cardiology, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of China; 2Nursing Department, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of China
Correspondence: Hongjian Zheng, Nursing Department, Chun’an First People’s Hospital, No. 1869 Huanhubei Road, Hangzhou, Zhejiang Province, 311700, People’s Republic of China, Email Zhenghj1245@163.com
Abstract: Myocardial infarction remains a major contributor to global morbidity and mortality, with current therapeutic strategies often falling short in addressing post-infarction inflammation, fibrotic remodeling, and suboptimal drug localization. Macrophages are key modulators of the cardiac immune microenvironment, play a dual role in tissue damage and repair by polarizing into distinct inflammatory and reparative phenotypes. Recent advancements in biomimetic nanotechnology have facilitated the development of macrophage membrane-coated nanocarrier engineered systems that replicate the functional surface characteristics of native macrophages. These nanocarriers offer enhanced therapeutic precision by enabling immune evasion, targeted delivery to infarcted myocardium, and sustained release of bioactive agents. Their prolonged systemic circulation further augments therapeutic efficacy. Current clinical strategies remain insufficient in preventing long-term complications such as adverse cardiac remodeling and the development of heart failure, highlighting a critical need for targeted and effective post-MI therapies. This review comprehensively evaluates the biological role of macrophages in the context of myocardial infarction and highlights current innovations in the fabrication and functional optimization of macrophage membrane-coated nanocarriers. We further discuss their mechanisms of action, therapeutic benefits demonstrated in preclinical models, and their prospective integration into regenerative treatment paradigms. Critical challenges, including regulatory approval, manufacturing scalability, and clinical translation, are also discussed. These nanocarriers represent a promising frontier in myocardial infarction therapy, offering targeted, biocompatible, and immune-responsive drug delivery platforms.
Keywords: macrophage membrane-coated nanocarriers, myocardial infarction therapy, biomimetic drug delivery systems, cardiac tissue regeneration, immune modulation in heart repair, targeted nanomedicine, translational nanotechnology
1Department of Cardiology, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of China; 2Nursing Department, Chun’an First People’s Hospital, Hangzhou, Zhejiang Province, 311700, People’s Republic of China
Correspondence: Hongjian Zheng, Nursing Department, Chun’an First People’s Hospital, No. 1869 Huanhubei Road, Hangzhou, Zhejiang Province, 311700, People’s Republic of China, Email Zhenghj1245@163.com
Abstract: Myocardial infarction remains a major contributor to global morbidity and mortality, with current therapeutic strategies often falling short in addressing post-infarction inflammation, fibrotic remodeling, and suboptimal drug localization. Macrophages are key modulators of the cardiac immune microenvironment, play a dual role in tissue damage and repair by polarizing into distinct inflammatory and reparative phenotypes. Recent advancements in biomimetic nanotechnology have facilitated the development of macrophage membrane-coated nanocarrier engineered systems that replicate the functional surface characteristics of native macrophages. These nanocarriers offer enhanced therapeutic precision by enabling immune evasion, targeted delivery to infarcted myocardium, and sustained release of bioactive agents. Their prolonged systemic circulation further augments therapeutic efficacy. Current clinical strategies remain insufficient in preventing long-term complications such as adverse cardiac remodeling and the development of heart failure, highlighting a critical need for targeted and effective post-MI therapies. This review comprehensively evaluates the biological role of macrophages in the context of myocardial infarction and highlights current innovations in the fabrication and functional optimization of macrophage membrane-coated nanocarriers. We further discuss their mechanisms of action, therapeutic benefits demonstrated in preclinical models, and their prospective integration into regenerative treatment paradigms. Critical challenges, including regulatory approval, manufacturing scalability, and clinical translation, are also discussed. These nanocarriers represent a promising frontier in myocardial infarction therapy, offering targeted, biocompatible, and immune-responsive drug delivery platforms.
Keywords: macrophage membrane-coated nanocarriers, myocardial infarction therapy, biomimetic drug delivery systems, cardiac tissue regeneration, immune modulation in heart repair, targeted nanomedicine, translational nanotechnology